CorFlow Therapeutics is developing a technology to identify and treat microvascular obstruction (MVO) in heart attack patients. MVO is common in acute heart attack patients and comes along with a poor prognosis.
Innosuisse – the Swiss Innovation Agency – previously supported the technology’s non-clinical development. Now, it is granting 1.7 million francs over two years to the project, according to a statement. The new grant will support clinical trials, with the first trial on human participants soon to start in Switzerland. For the trials, CorFlow is working with researchers from Swiss universities including the University of Zurich and the Federal Institute of Technology in Zurich (ETH).
CorFlow is also helping finance the clinical trial. It has raised 9.4 million francs from private investors in a seed funding round. In 2019, it plans to run a series A financing round to finance further development and clinical and regulatory activities.
More News
Meet with an expansion expert
Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center? Give us a call or drop us a line.